Bevacizumab (Avastin) Pharmacokinetic ELISA
Bevacizumab (Trade name Avastin®) is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A) . VEGF-A stimulates angiogenesis in a variety of diseases, including cancer. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States. Bevacizumab was approved by the U.S. Food and Drug Administration (FDA) for certain metastatic cancers. It received its first approval in 2004, for combined use with standard chemotherapy for metastatic colon cancer. It has since been approved for use in certain lung cancers, renal cancers, ovarian cancers, and glioblastoma multiforme of the brain. It had been approved for breast cancer, but that approval was withdrawn when later studies showed no evidence of effectiveness
Product Specifications
CAS Number
7732-18-5
Gene ID
7422
Reactivity
Human, mouse, rat
Reaction Volume
15 µL
Target Antigen
Bevacizumab (Avastin)
Detection Method
Peroxidase / OD450
Assay Type
ELISA
Assay Principle
Quantification of Bevacizumab in biological matrices
Assay Protocol
Assay Performance Time
2.5 hours
Sample Type
Serum Plasma
Sample Volume
15ul
Detection Range
50ng/ml - 1.56ng/ml
Precision
<10%, <10%
Sensitivity
Bevacizumab
Limit Of Detection
1.5ng/ml
Components
Shipping Conditions
Blue Ice
Storage Conditions
-20C, 1 year
Shelf Life
12 months
Badge
Hot
Specificity
Bevacizumab
Method
Direct sandwich ELISA
Preservative
None
Preparation
Operating Procedure
Results Calculation
Sample Collection
This kit is compatible with EDTA-plasma, heparinplasma and serum samples. Samples can be stored at or below -20°C for up to 1 year.
Sample Preparation
Plate
Strip
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items